MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Pleural

Malignant pleural mesothelioma; mesothelioma of the lining of the lungs, or pleura.

Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma.

Histopathology 2020 March 14 [Link] Bilecz A, Stockhammer P, Theegarten D, Kern I, Jakopovic M, Samarzija M, Klikovits T, Hoda MA, Döme B, Oberndorfer F, Muellauer L, Fillinger J, Kovács I, Pirker C, Schuler M, Plönes T, Aigner C, Klepetko W, Berger W, Brcic L, Laszlo V, Hegedus B Abstract AIMS: Malignant pleural mesothelioma (MPM) […]

Comments Off on Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma.

Comprehensive molecular and pathological evaluation of transitional mesothelioma assisted by deep learning approach: a multi institutional study of the International Mesothelioma Panel from MESOPATH Reference Center.

Journal of Thoracic Oncology 2020 March 9 [Link] Salle FG, Le Stang N, Tirode F, Courtiol P, Nicholson AG, Tsao MS, Tazelaar HD, Churg A, Dacic S, Roggli V, Pissaloux D, Maussion C, Moarii M, Beasley MB, Begueret H, Chapel DB, Copin MC, Gibbs AR, Klebe S, Lantuejoul S, Nabeshima K, Vignaud JM, Attanoos R, […]

Comments Off on Comprehensive molecular and pathological evaluation of transitional mesothelioma assisted by deep learning approach: a multi institutional study of the International Mesothelioma Panel from MESOPATH Reference Center.

Curcumin as an Anticancer Agent in Malignant Mesothelioma: A Review.

International Journal of Molecular Science 2020 March 7 [Link] Baldi A, De Luca A, Maiorano P, D’Angelo C, Giordano A Abstract Malignant mesothelioma is an infrequent tumor that initiates from the mesothelial cells lining of body cavities. The great majority of mesotheliomas originate in the pleural cavity, while the remaining cases initiate in the peritoneal […]

Comments Off on Curcumin as an Anticancer Agent in Malignant Mesothelioma: A Review.

Immunotherapy in Malignant Pleural Mesothelioma.

Frontiers in Oncology 2020 February 21 [Link] de Gooijer CJ, Borm FJ, Scherpereel A, Baas P Abstract The only registered systemic treatment for malignant pleural mesothelioma (MPM) is platinum based chemotherapy combined with pemetrexed, with or without bevacizumab. Immunotherapy did seem active in small phase II trials. In this review, we will highlight the most […]

Comments Off on Immunotherapy in Malignant Pleural Mesothelioma.

How I treat malignant pleural mesothelioma.

ESMO Open 2020 March [Link] Viscardi G, Di Liello R, Morgillo F Abstract Malignant pleural mesothelioma is a rare and aggressive malignancy mostly associated with occupational asbestos exposure. Prognosis is poor and only highly selected patients may benefit from aggressive surgical management, also as part of a multimodal approach. In advanced disease, the combination of […]

Comments Off on How I treat malignant pleural mesothelioma.

ADAR2 Regulates Malignant Behaviour of Mesothelioma Cells Independent of RNA-editing Activity.

Anticancer Research 2020 March [Link] Sakata KI, Maeda K, Sakurai N, Liang S, Nakazawa S, Yanagihara K, Kubo T, Yoshiyama H, Kitagawa Y, Hamada JI, Iizasa H Abstract BACKGROUND/AIM: Malignant pleural mesothelioma (MPM) is an intractable cancer, and causes of its malignant transformation are not well known. Adenosine deaminase acting on RNA (ADAR) is an […]

Comments Off on ADAR2 Regulates Malignant Behaviour of Mesothelioma Cells Independent of RNA-editing Activity.

Histopathological features of epithelioid malignant pleural mesotheliomas in patients with extended survival.

Human Pathology 2020 March 3 [Link] Paajanen J, Laaksonen S, Kettunen E, Ilonen I, Vehmas T, Salo J, Räsänen J, Sutinen BHc E, Ollila BHc H, Mäyränpää MI, Myllärniemi M, Wolff H Abstract Diffuse malignant mesothelioma (DMM) of the pleura is a rare and aggressive disease, where the long-term survival (LTS) rate is low. The […]

Comments Off on Histopathological features of epithelioid malignant pleural mesotheliomas in patients with extended survival.

Malignant mesothelioma cells secrete natriuretic peptides: Data and diagnostic clinical implications.

Respirology 2020 March 2 [Link] Tsolaki V, Zarogiannis S, Zygoulis P, Kalomenidis I, Jagirdar R, Makris D, Daniil Z, Magkouta S, Triantafyllou I, Papanikolaou J, Gourgoulianis KI, Zakynthinos E Abstract BACKGROUND AND OBJECTIVE: Mesothelial cells and cardiomyocytes have shared embryonic mesodermal origin. Cardiomyocytes release BNP under stretch. We searched whether malignant mesothelioma cells also secrete […]

Comments Off on Malignant mesothelioma cells secrete natriuretic peptides: Data and diagnostic clinical implications.

Routine surveillance for diagnosis of venous thromboembolism after pleurectomy for malignant pleural mesothelioma.

The Journal of Thoracic and Cardiovascular Surgery 2020 January 30 [Link] De León LE, Bravo-Iñiguez CE, Fox S, Tarascio J, Freyaldenhoven S, Lapidot M, Jaklitsch MT, Bueno R Abstract OBJECTIVE: The purpose of this study was to determine the incidence of venous thromboembolism and utility of a routine surveillance program in patients undergoing surgery for […]

Comments Off on Routine surveillance for diagnosis of venous thromboembolism after pleurectomy for malignant pleural mesothelioma.

A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Lung Cancer 2020 February 12 [Link] Zucali PA, Perrino M, De Vincenzo F, Giordano L, Cordua N, D’Antonio F, Santoro A Abstract OBJECTIVES: Second-line chemotherapy is not a standard of care in patients with malignant pleural mesothelioma (MPM) that progresses after first-line treatment with cisplatin and pemetrexed. In pre-clinical models, the combination of gemcitabine (GEM) […]

Comments Off on A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.